Vigabatrin liquid pharmaceutical composition
US12290499B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 28, 2024 |
| Grant date | May 6, 2025 |
| Priority date | — |
| Expiry date | Jun 28, 2044 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The embodiments of the present invention relate to a stable liquid vigabatrin pharmaceutical compositions in the liquid form of a solution. Particularly, the stable vigabatrin liquid pharmaceutical composition is manufactured as a ready-to-use industrialized premixture that does not require reconstitution or dilution prior to administration to a patient. The vigabatrin liquid pharmaceutical composition is stable six months or longer at room temperature and has levels of total impurities and Vigabatrin-related compound A that are both not more than 0.04% at, or prior to, six months. In some embodiments, the composition has improved stability and patient compliance. In some embodiments, the compositions may be advantageous for the patients having swallowing difficulties or when the patients are unable to take solid oral dosage forms. In some embodiments, the composition improves compliance with ketogenic diet.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.